Algatech yeast infection women licenses technology to optimise beta-glucans extraction

Algatech has licensed the rights and intellectual property related to yeast infection women the production of β-1,3-glucan from US biotech F3 platform biologics (“F3”). This new technology makes the extraction from the microalgae more yeast infection women efficient and produces a higher-quality ingredient than previously possible.

The technology licensed by algatech derives β-1,3-glucans from fermented microalgae euglena gracilis. The β-1,3-glucans can constitute up to 60% of the ingredient. Β-1,3-glucans are currently widely available in the market from several yeast infection women sources including yeast, oats and mushrooms, however when derived from euglena gracilis they are more concentrated yeast infection women and purer in their make-up due to their chemical structure and processing techniques. This makes them significantly more potent and effective in terms yeast infection women of their potential health benefits for both humans and animals.

The technology has been licensed from F3 platform biologics who yeast infection women developed it under the product name bioglenay. Through this new technology, algatech’s vision is to bring these more efficient and better yeast infection women quality β-1,3-glucans-based products to market.

Commenting on the deal, hagai stadler, CEO of algatech, said: “currently only a tiny fraction of the world’s microalgae has been developed for commercial use, despite the vast potential these organisms can have in tackling yeast infection women societal health issues.”

In order to capitalise on the wide-reaching benefits of microalgae-derived β-1,3-glucans and a largely untapped market, algatech is planning to launch several products using the nutrient yeast infection women for both the human and animal health markets in the yeast infection women coming months. These products will expand algatech’s existing product offering and support its mission to develop yeast infection women commercial, microalgae-based products with the potential to tackle some of society’s most pressing wellbeing and health challenges.

Stadler said: “we expect to launch the first euglena-based product in the coming months and, following the launch of fucovital last year, it will be algatech’s third commercial product. Additionally, our experienced R&D team continue to explore and develop other promising health yeast infection women ingredients derived from microalgae, with wide-ranging benefits, which will be launched over the following years.”

Β-1,3-glucans are produced and processed at varied levels to make yeast infection women powdered products in market leading concentrated forms to minimally processed yeast infection women offerings additionally rich in protein, healthy fats and 23 other vitamins. Studies show that these properties make it an invaluable tool yeast infection women for boosting human immunity, increasing the body’s antibodies by 84% and supporting its ability to fight infection. Many of these benefits to human health also apply to yeast infection women animals – enhanced β-1,3-glucan intake has been proven to prime immune systems and yeast infection women support growth at optimal rates. In practice, the powder product can be added to shakes, protein drinks, nutritional bars, cookies, yogurt, puddings and chocolate for added health benefits, making it accessible and affordable for mass market consumption.

Algatech has licensed the rights and intellectual property related to yeast infection women the production of β-1,3-glucan from US biotech F3 platform biologics (“F3”). This new technology makes the extraction from the microalgae more yeast infection women efficient and produces a higher-quality ingredient than previously possible.

The technology licensed by algatech derives β-1,3-glucans from fermented microalgae euglena gracilis. The β-1,3-glucans can constitute up to 60% of the ingredient. Β-1,3-glucans are currently widely available in the market from several yeast infection women sources including yeast, oats and mushrooms, however when derived from euglena gracilis they are more concentrated yeast infection women and purer in their make-up due to their chemical structure and processing techniques. This makes them significantly more potent and effective in terms yeast infection women of their potential health benefits for both humans and animals.

The technology has been licensed from F3 platform biologics who yeast infection women developed it under the product name bioglenay. Through this new technology, algatech’s vision is to bring these more efficient and better yeast infection women quality β-1,3-glucans-based products to market.

Commenting on the deal, hagai stadler, CEO of algatech, said: “currently only a tiny fraction of the world’s microalgae has been developed for commercial use, despite the vast potential these organisms can have in tackling yeast infection women societal health issues.”

In order to capitalise on the wide-reaching benefits of microalgae-derived β-1,3-glucans and a largely untapped market, algatech is planning to launch several products using the nutrient yeast infection women for both the human and animal health markets in the yeast infection women coming months. These products will expand algatech’s existing product offering and support its mission to develop yeast infection women commercial, microalgae-based products with the potential to tackle some of society’s most pressing wellbeing and health challenges.

Stadler said: “we expect to launch the first euglena-based product in the coming months and, following the launch of fucovital last year, it will be algatech’s third commercial product. Additionally, our experienced R&D team continue to explore and develop other promising health yeast infection women ingredients derived from microalgae, with wide-ranging benefits, which will be launched over the following years.”

Β-1,3-glucans are produced and processed at varied levels to make yeast infection women powdered products in market leading concentrated forms to minimally processed yeast infection women offerings additionally rich in protein, healthy fats and 23 other vitamins. Studies show that these properties make it an invaluable tool yeast infection women for boosting human immunity, increasing the body’s antibodies by 84% and supporting its ability to fight infection. Many of these benefits to human health also apply to yeast infection women animals – enhanced β-1,3-glucan intake has been proven to prime immune systems and yeast infection women support growth at optimal rates. In practice, the powder product can be added to shakes, protein drinks, nutritional bars, cookies, yogurt, puddings and chocolate for added health benefits, making it accessible and affordable for mass market consumption.

RELATED POSTS